Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help ...

The approval comes as two Alzheimer's drugs—lecanemab and donanemab—are already authorized by the FDA. Both are antibody therapies that target amyloid plaques and are believed to be more effective ...

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

The FDA greenlit marketing for the first blood test to help diagnose Alzheimer’s disease. Experts believe this will increase ...

The FDA cleared the first blood test on Friday to help diagnose Alzheimer's disease among older Americans already exhibiting ...

New blood test approved for Alzheimer's diagnosis. The test measures two proteins in blood plasma, correlating with amyloid plaques in the brain.